0001062993-21-000339.txt : 20210113
0001062993-21-000339.hdr.sgml : 20210113
20210113161118
ACCESSION NUMBER: 0001062993-21-000339
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210111
FILED AS OF DATE: 20210113
DATE AS OF CHANGE: 20210113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Petrova Penka
CENTRAL INDEX KEY: 0001838044
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36596
FILM NUMBER: 21526190
MAIL ADDRESS:
STREET 1: C/O TRILLIUM THERAPEUTICS INC.
STREET 2: 2488 DUNWIN DRIVE
CITY: MISSISSAUGA
STATE: A6
ZIP: L5L 1J9
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Trillium Therapeutics Inc.
CENTRAL INDEX KEY: 0001616212
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A6
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2488 DUNWIN DRIVE
CITY: MISSISSAUGA
STATE: A6
ZIP: L5L 1J9
BUSINESS PHONE: (416) 595-0627
MAIL ADDRESS:
STREET 1: 2488 DUNWIN DRIVE
CITY: MISSISSAUGA
STATE: A6
ZIP: L5L 1J9
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2021-01-11
0001616212
Trillium Therapeutics Inc.
TRIL
0001838044
Petrova Penka
C/O TRILLIUM THERAPEUTICS INC.
2488 DUNWIN DRIVE
MISSISSAUGA
A6
L5L 1J9
ONTARIO, CANADA
0
1
0
0
Chief Development Officer
Common Shares
2021-01-11
4
M
0
508
9.5671
A
508
D
Common Shares
2021-01-11
4
S
0
508
15.2073
D
0
D
Stock Option (Right to Buy)
9.5671
2021-01-11
4
M
0
508
0
D
2027-11-09
Common Shares
508
5082
D
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The exercise price of these options is $12.22 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7829 USD.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.15 to $15.31 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.
/s/ James Parsons, Attorney-in-Fact
2021-01-13